TRAF2 and breast carcinoma: Interestingly, it has been reported that receptor activator of NFκB (RANK)-c, a splice form of the TRAF2-interacting TNFR RANK, which is found in 3.2% of breast cancer patients and which acts in a dominant-negative fashion on RANK-induced NFκB activation, is inversely correlated with disease grade [242,243].